YUHAN CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 72,300 KRW | -1.23% |
|
+4.33% | +5.09% |
| 09:18am | Korean Sugar Imports Plunge 14% as Diabetes Cases Surge | MT |
| Mar. 07 | Yuhan Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 2,083B 1.51B | Sales 2025 * | 2,293B 1.67B | Capitalization | 5,390B 3.92B |
|---|---|---|---|---|---|
| Net income 2024 * | 174B 126M | Net income 2025 * | 218B 158M | EV / Sales 2024 * | 2.46 x |
| Net cash position 2024 * | 274B 199M | Net cash position 2025 * | 407B 296M | EV / Sales 2025 * | 2.17 x |
| P/E ratio 2024 * |
35.2
x | P/E ratio 2025 * |
27.7
x | Employees | 1,999 |
| Yield 2024 * |
0.54% | Yield 2025 * |
0.55% | Free-Float | 67.3% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.23% | ||
| 1 week | +5.63% | ||
| Current month | -4.56% | ||
| 1 month | -4.06% | ||
| 3 months | +21.59% | ||
| 6 months | +23.97% | ||
| Current year | +6.40% |
1 week
67 800.00
74 200.00
1 month
67 800.0083 400.00
Current year
57 500.0083 400.00
1 year
52 285.7184 190.48
3 years
47 571.4384 190.48
5 years
30 851.3484 190.48
10 years
21 997.2884 190.48
| Managers | Title | Age | Since |
|---|---|---|---|
Wuk-Jae Cho
CEO | Chief Executive Officer | 69 | 87-04-30 |
Jeong-Hui Lee
CHM | Chairman | 72 | 78-04-30 |
Byeong-Man Lee
BRD | Director/Board Member | 66 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jeong-Hui Lee
CHM | Chairman | 72 | 78-04-30 |
Wuk-Jae Cho
CEO | Chief Executive Officer | 69 | 87-04-30 |
Byeong-Man Lee
BRD | Director/Board Member | 66 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.53% | 2 M€ | -14.14% | ||
| 0.10% | 11 M€ | +0.34% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 72,300 | -1.23% | 332 436 |
| 24-04-23 | 73,200 | +2.23% | 320,085 |
| 24-04-22 | 71,600 | +3.32% | 516,293 |
| 24-04-19 | 69,300 | -1.14% | 310,670 |
| 24-04-18 | 70,100 | +2.34% | 242,556 |
End-of-day quote Korea S.E., April 22, 2024
More quotes
Yuhan Corp is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical segment is engaged in the production and sale of non-prescription drugs including anti-inflammatory drugs, as well as prescription drugs such as drugs for hepatitis, diabetes, and hypertension. The Life and Health segment is involved in the production and sale of household goods and animal healthcare (AHC) products, including bleach, antibacterial agents. The Overseas Business segment supplies raw drugs to domestic and overseas markets. The Company also sells licenses. The Company distributes its products in domestic and overseas markets such as Europe, Asia and United States.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
73,200
KRW
Average target price
85,674
KRW
Spread / Average Target
+17.04%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +6.40% | 3.97B | |
| +11.94% | 9.18B | |
| -16.33% | 4.79B | |
| +26.98% | 3.98B | |
| +28.52% | 2.56B | |
| -26.55% | 2.29B | |
| -25.02% | 2.23B | |
| +5.82% | 1.92B | |
| -0.50% | 1.64B | |
| +3.49% | 1.64B |
- Stock Market
- Equities
- A000100 Stock
